keyword
MENU ▼
Read by QxMD icon Read
search

Graves orbitopathy

keyword
https://www.readbyqxmd.com/read/28755510/raising-awareness-of-graves-orbitopathy-with-early-warning-cards
#1
Anna Mitchell, Janis Hickey, Bijay Vaidya, Rhianne Mason, Ramzi Ajjan, Nicola Zammitt, Petros Perros, Colin Dayan
BACKGROUND: Clinically significant Graves' orbitopathy (GO) develops in about 25% of those with Graves' disease (GD); most cases of GD in the UK are managed by endocrinologists. Despite this, patients report significant delays before a diagnosis of GO is made. Measures to increase awareness of the early signs of GO and establishing a fast-track referral pathway to specialist care should overcome these delays and potentially improve outcomes. AIMS: We aimed to determine whether issuing a "GO early warning card" to all GD patients raises awareness of GO and facilitates early diagnosis, what percentage of cards result in a telephone contact, the number of "false reports" from card carriers and patient perceptions of the cards...
July 29, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/28748990/-clinical-features-of-patients-with-basedow-graves-disease-seen-at-a-university-hospital
#2
Alejandra Lanas, Patricia Díaz, Daniela Eugenin, Franco González, Pía Cid, Francisco Cordero, Verónica Araya, Claudio Liberman, Marcela Barberan, Patricio Gac, Neil Saldías, Pedro Pineda
BACKGROUND: Basedow Graves disease (BGD) is the leading cause of hyperthyroidism. The characteristics of patients seen at a university hospital may differ from those described in the general population. AIM: To describe the clinical features of patients with BGD seen at a university hospital. MATERIAL AND METHODS: Review of medical records of all patients seen at our hospital between 2009 and 2014 with the diagnosis of thyrotoxicosis, hyperthyroidism or BGD...
April 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/28741406/balanced-endoscopic-medial-and-transcutaneous-lateral-orbital-decompression-in-graves-orbitopathy
#3
Estefanía Hernández-García, J Javier San-Román, Ramón González, Araceli Nogueira, Ignacio Genol, Bazil Stoica, Nicolás Toledano, Guillermo Plaza
BACKGROUND: To determine the clinical outcomes and morbidity of endoscopic medial wall combined with transcutaneous lateral orbital wall decompression in Graves' orbitopathy. METHODOLOGY: A retrospective noncomparative case series of patients who underwent surgical decompression for Graves' orbitopathy at Hospital Universitario de Fuenlabrada between 2004 and 2014 was performed. We reviewed the patients' charts and analyzed before and after the decompression, the visual acuity (Snellen chart), optic nerve compression (fundoscopy and optic coherence tomography), exophthalmometry (Hertel measurement), ocular motility, diplopia, eyelid surgery needed after decompression and its possible complications...
July 25, 2017: Acta Oto-laryngologica
https://www.readbyqxmd.com/read/28660988/clinical-and-immunological-changes-in-patients-with-active-moderate-to-severe-graves%C3%AC-orbitopathy-treated-with-very-low-dose-rituximab
#4
David Karasek, Lubica Cibickova, Marta Karhanova, Jana Kalitova, Jan Schovanek, Zdenek Frysak
INTRODUCTION: Glucocorticoids represent the therapy of choice for active and moderate-to-severe Graves̕ orbitopathy (GO). In some patients, rituximab, a monoclonal antibody against the cluster of differentiation (CD) 20 receptor of B-lymphocytes, can serve as a second-line or an alternative treatment. The effect of very low-doseof rituximabon the clinical activity of GO and corresponding clinical or laboratory changes is reported. MATERIAL AND METHODS: Changes of Clinical Activity Score (CAS) for GO, proptosis, levels of thyroid-stimulating hormone receptor antibodies, and depletion of CD19+ and CD20+ B-lymphocytes were determined in ten patients (two men and eight women) with active moderate-to-severe GO treated with a single 100-mg dose of rituximab...
June 29, 2017: Endokrynologia Polska
https://www.readbyqxmd.com/read/28656526/action-of-three-bioavailable-antioxidants-in-orbital-fibroblasts-from-patients-with-graves-orbitopathy-go-a-new-frontier-for-go-treatment
#5
G Rotondo Dottore, I Ionni, F Menconi, G Casini, S Sellari-Franceschini, M Nardi, P Vitti, C Marcocci, M Marinò
OBJECTIVE: Oxidative stress is involved in the pathogenesis of Graves' orbitopathy (GO) and an antioxidant approach has been advocated for GO treatment. Here, we investigated the action of three antioxidants in orbital fibroblasts, namely, vitamin C, N-acetyl-L-cysteine, and melatonin. METHODS: Primary cultures of orbital fibroblasts from six GO patients and six control subjects were established. Cells were treated with H2O2 to induce oxidative stress. Cell vitality assays were performed to determine the non-cytotoxic dose of each antioxidant...
June 27, 2017: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/28639965/is-selenium-supplementation-in-autoimmune-thyroid-diseases-justified
#6
Kristian H Winther, Steen Bonnema, Laszlo Hegedüs
PURPOSE OF REVIEW: This review provides an appraisal of recent evidence for or against selenium supplementation in patients with autoimmune thyroid diseases, and discusses possible effect mechanisms. RECENT FINDINGS: Epidemiological data suggest an increased prevalence of autoimmune thyroid diseases under conditions of low dietary selenium intake. Two systematic reviews have evaluated controlled trials among patients with autoimmune thyroiditis and report that selenium supplementation decreases circulating thyroid autoantibodies...
July 20, 2017: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/28634704/teprotumumab-a-new-avenue-for-the-management-of-moderate-to-severe-and-active-graves-orbitopathy
#7
E Piantanida, L Bartalena
No abstract text is available yet for this article.
August 2017: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/28604944/the-influence-of-graves-orbitopathy-treatment-with-intravenous-glucocorticoids-on-adrenal-function
#8
Urszula Ambroziak, Gabriela Bluszcz, Tomasz Bednarczuk, Piotr Miśkiewicz
INTRODUCTION: Graves' orbitopathy (GO) is the commonest extrathyroidal feature of Graves' disease. For active, moderate to severe GO intravenous glucocorticoid pulse therapy (ivGCS) is the first-line treatment, which might be followed by oral glucocorticoid therapy. Glucocorticoid treatment, especially in the time of withdrawal, carries a risk of adrenal insufficiency. The aim of this study was to assess the pituitary-adrenal axis function in patients with GO before and at the cessation of ivGCS, and after further oral glucocorticoid therapy...
June 12, 2017: Endokrynologia Polska
https://www.readbyqxmd.com/read/28548552/serum-cyr61-is-associated-with-disease-activity-in-graves-orbitopathy
#9
Young Jun Woo, Yuri Seo, Jin Joo Kim, Ji Won Kim, Yil Park, Jin Sook Yoon
PURPOSE: To investigate the clinical implications of cysteine-rich angiogenic inducer 61 (CYR61) in Graves' orbitopathy (GO). METHODS: Sera from 52 GO patients, 23 Graves' disease (GD) patients, and 20 healthy controls, and orbital fat tissue samples from 12 of 52 GO patients and 8 control subjects were included for analysis. Concentrations of CYR61 were measured from sera with an enzyme-linked immunosorbent assay, and CYR61 mRNA expression levels were evaluated from orbital fat tissue with polymerase chain reaction...
May 26, 2017: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/28540010/changes-in-choroidal-perfusion-after-orbital-decompression-surgery-for-graves-ophthalmopathy
#10
Narieman Nik, Amelia Fong, Marianna Derdzakyan, Chrysavgi Adamopoulou, Adam Sise, Aziz Khanifar, Reginald Sanders
PURPOSE: To assess choroidal perfusion before and after orbital decompression surgery in patients with Graves' ophthalmopathy. METHODS: In this interventional case series, surgical decompression for optic nerve compromise was performed on four eyes of three patients with Graves' disease. Complete ophthalmic examination including visual acuity, color vision, and intraocular pressure assessment were done pre- and postoperatively. High-speed indocyanine green angiography was performed prior to surgery and was repeated one year after surgery...
April 2017: Journal of Ophthalmic & Vision Research
https://www.readbyqxmd.com/read/28492873/sphingosine-1-phosphate-mediates-fibrosis-in-orbital-fibroblasts-in-graves-orbitopathy
#11
JaeSang Ko, Min Kyoung Chae, Joon H Lee, Eun Jig Lee, Jin Sook Yoon
Purpose: To investigate the effect of sphingosine-1-phosphate (S1P) on fibrosis in orbital fibroblasts in Graves' orbitopathy (GO). Methods: Orbital fibroblasts were cultured from orbital adipose/connective tissues of patients with GO and healthy control subjects. Effects of treatment with TGF-β and cigarette smoke extract (CSE) on S1P receptor (S1PR) messenger RNA (mRNA) and S1P expression were evaluated by real-time polymerase chain reaction and Western blotting...
May 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28457289/changes-in-pupillary-distance-after-fat-versus-bony-orbital-decompression-in-graves-orbitopathy
#12
Young Jun Woo, Jin Sook Yoon
OBJECTIVE: To report changes in pupillary distance (PD) after orbital decompression in patients with Graves' orbitopathy (GO). DESIGN: Retrospective comparative case series. PARTICIPANTS: A total of 59 cases who underwent the same type of orbital decompression on both eyes. METHODS: The medical records of 111 patients who underwent orbital decompression were reviewed retrospectively. Fifty-nine patients without restrictive myopathy who underwent the same procedure on both eyes were included...
April 2017: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
https://www.readbyqxmd.com/read/28450378/long-term-outcomes-of-orbital-fat-decompression-in-graves-orbitopathy
#13
Anny M Cheng, Yi-Hsuan Wei, Sean Tighe, Hosam Sheha, Shu-Lang Liao
PURPOSE: To evaluate the long-term clinical efficacy of orbital fat decompression in treating proptosis in Graves' ophthalmopathy (GO). METHODS: Retrospective review of 1604 eyes of 845 patients with symmetric (1518 eyes) and asymmetric (86 eyes) proptosis who received orbital fat decompression between 2003 and 2014. Changes in Hertel values were evaluated at baseline, 6 months postoperatively and yearly thereafter. Recurrence of proptosis, diplopia and other complications that required additional surgeries were documented and analysed...
April 27, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28439882/prevalence-and-clinical-relevance-of-thyroid-stimulating-hormone-receptor-blocking-antibodies-in-autoimmune-thyroid-disease
#14
T Diana, J Krause, P D Olivo, J König, M Kanitz, B Decallonne, G J Kahaly
The prevalence and clinical relevance of thyroid stimulating hormone (TSH) receptor (TSHR) blocking antibodies (TBAb) in patients with autoimmune thyroid disease (AITD) was investigated. Serum TBAb were measured with a reporter gene bioassay using Chinese hamster ovary cells. Blocking activity was defined as percentage inhibition of luciferase expression relative to induction with bovine TSH alone (cut-off 40% inhibition). All samples were measured for TSHR stimulatory antibody (TSAb) and TSHR binding inhibiting immunoglobulins (TBII)...
September 2017: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/28427469/graves-orbitopathy-as-a-rare-disease-in-europe-a-european-group-on-graves-orbitopathy-eugogo-position-statement
#15
P Perros, L Hegedüs, L Bartalena, C Marcocci, G J Kahaly, L Baldeschi, M Salvi, J H Lazarus, A Eckstein, S Pitz, K Boboridis, P Anagnostis, G Ayvaz, A Boschi, T H Brix, N Currò, O Konuk, M Marinò, A L Mitchell, B Stankovic, F B Törüner, G von Arx, M Zarković, W M Wiersinga
BACKGROUND: Graves' orbitopathy (GO) is an autoimmune condition, which is associated with poor clinical outcomes including impaired quality of life and socio-economic status. Current evidence suggests that the incidence of GO in Europe may be declining, however data on the prevalence of this disease are sparse. Several clinical variants of GO exist, including euthyroid GO, recently listed as a rare disease in Europe (ORPHA466682). The objective was to estimate the prevalence of GO and its clinical variants in Europe, based on available literature, and to consider whether they may potentially qualify as rare...
April 20, 2017: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/28419103/establishment-of-a-tear-protein-biomarker-panel-differentiating-between-graves-disease-with-or-without-orbitopathy
#16
Cecilie Aass, Ingrid Norheim, Erik Fink Eriksen, Ellen Charlotte Børnick, Per Medbøe Thorsby, Milaim Pepaj
BACKGROUND: Graves' orbitopathy (GO) is an autoimmune inflammatory ocular complication and one of the most frequent manifestations of Graves' disease (GD). Clinical judgment of GO is subjective sometimes leading to clinical and therapeutic challenges. Better tools to diagnose this severe complication are warranted. PATIENTS AND METHODS: The aim of the present study was to evaluate tear levels of LYZ, LACRT and AZGP1 in GD patients with or without GO, as possible biomarkers for GO...
2017: PloS One
https://www.readbyqxmd.com/read/28379055/performance-of-apparent-diffusion-coefficient-of-medial-and-lateral-rectus-muscles-in-graves-orbitopathy
#17
Ahmed Ak Abdel Razek, Mohamed El-Hadidy, Mohamed E Moawad, Nader El-Metwaly, Amr A El-Said
Objective The purpose of this study was to determine the performance of the apparent diffusion coefficient in the detection of involvement of the medial and lateral rectus muscles in patients with Graves' orbitopathy. Methods and materials This prospective study was conducted on 33 consecutive patients (16 males, 17 females with a mean age of 36 years) with Graves' orbitopathy and 18 age- and sex-matched volunteers. The patients and volunteers underwent diffusion-weighted magnetic resonance imaging of the orbit in the axial plane using echo-planar imaging...
June 2017: Neuroradiology Journal
https://www.readbyqxmd.com/read/28368444/cyclic-peptides-for-effective-treatment-in-a-long-term-model-of-graves%C3%A2-disease-and-orbitopathy-in-female-mice
#18
Hans-Peter Holthoff, Zhongmin Li, Julia Faßbender, Andreas Reimann, Kristin Adler, Götz Münch, Martin Ungerer
A model for human Graves´ disease in mice was used to compare several novel treatment approaches. The mice received regular adenoviral (Ad) thyroid-stimulating receptor (TSHR) A subunit immunisations (4-weekly injections). Generation of anti-TSHR antibodies, enlarged thyroid sizes (goiter), elevated serum thyroxin levels, retro-orbital fibrosis and cardiac involvement (tachycardia and hypertrophy) were consistently observed during 9 months.Treatment of established disease in these mice with novel cyclic peptides which mimic one of the cylindrical loops of the TSHR leucin-rich repeat domain improved or even cured all investigated parameters after 6 consecutive monthly injections...
March 29, 2017: Endocrinology
https://www.readbyqxmd.com/read/28364200/sphingosine-1-phosphate-is-involved-in-inflammatory-reactions-in-patients-with-graves-orbitopathy
#19
Yuri Seo, Min Kyung Chae, Sol Ah Han, Eun Jig Lee, Joon H Lee, Jin Sook Yoon
OBJECTIVE: Graves' orbitopathy (GO) is initiated by excessive amount of various inflammatory mediators produced by orbital fibroblasts. This study aimed to assess the crucial role of sphingosine-1-phosphate (S1P) in the inflammatory process of GO. METHODS: Orbital adipose/connective tissue samples were obtained from 10 GO patients and 10 normal control individuals during surgery. Primary orbital fibroblast culture was done. After the expression of S1P receptors and sphingosine kinase (SphK) was assessed with the treatment of interleukin (IL)-1β, we evaluated the expression of pro-inflammatory factors [intercellular adhesion molecule-1 (ICAM-1), cyclooxygenase-2 (COX-2) and IL-6] after treating S1P...
March 31, 2017: Inflammation Research: Official Journal of the European Histamine Research Society ... [et Al.]
https://www.readbyqxmd.com/read/28258132/mortality-in-graves-orbitopathy-is-increased-and-influenced-by-gender-age-and-pre-existing-morbidity-a-nationwide-danish-register-study
#20
Charlotte F Schwensen, Frans Brandt, Laszlo Hegedüs, Thomas H Brix
INTRODUCTION: It is unclear whether the excess mortality associated with Graves' disease differs between individuals with Graves' orbitopathy (GO) or without (GD). SUBJECTS AND METHODS: A nationwide, register-based cohort study in which all adult Danes diagnosed with GD (n = 28 461) and GO (n = 3965) between 1995 and 2012 were matched for age and gender with four control subjects. Median follow-up time was 7.9 years (range 0-17.5). Mortality risk in GO patients compared to the control population and compared to GD patients was calculated using Cox regression analyses, adjusting for pre-existing morbidity using the Charlson score...
June 2017: European Journal of Endocrinology
keyword
keyword
20691
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"